Best peptides for cognitive enhancement, ranked by trial evidence.

When you're ranking the best peptides for cognitive enhancement, the useful work is separating molecules with real Russian stroke trials from ones with a marketing story and a thin evidence base. We've done that, and we've surfaced the negative Cochrane finding most consumer reviews skip.

Cognitive enhancement is the category where consumer marketing leans hardest on extrapolation. Trials run in stroke or ADHD populations get repackaged as “nootropic” claims for healthy adults. That extrapolation is sometimes biologically plausible and sometimes not.

The Russian-school neuropeptide work on Semax and Selank is methodologically older than current Western standards, but it's substantial and consistent across multiple labs. The Cerebrolysin literature has the opposite shape: clinical use in 50+ countries, but the 2023 Cochrane review on cognitive decline reads negatively. We'll walk through each on its own terms.

This piece ranks the five peptides most promoted for cognition by the actual depth of their published evidence. We identify the trial caveats vendor copy typically omits. And we flag where conventional cognitive treatment still wins.

How cognitive peptides support brain function

Across the cognitive peptides, a small number of mechanisms recur. We'll keep these short so you can map each peptide back to one.

• BDNF and NGF upregulation. BDNF is brain-derived neurotrophic factor, a protein that supports synaptic plasticity (the ability of neurons to form new connections). NGF is nerve growth factor. Both Semax and Selank are documented to raise these in preclinical models.
• Monoaminergic modulation. Effects on serotonin, dopamine, and noradrenaline systems. This underlies the anxiolytic and attention effects of Selank and Semax.
• Neuroprotection in ischemia models. Semax and Cerebrolysin have both been used as adjuncts in acute stroke based on rodent signals.
• Mitochondrial-energy support. The mechanism for NAD+ and SS-31. The cognitive-relevance argument depends on the assumption that mitochondrial dysfunction contributes to cognitive decline.

The standard caveat applies. A coherent mechanism in cell-culture work isn't evidence of efficacy in a person with a cognitive complaint. The bridge from mechanism to outcome is trial design. The trial designs across this list vary dramatically in quality.

Here are the five, side by side on the evidence, before we take each one in turn.

1. Semax: the Russian stroke-recovery and ADHD peptide

Semax is a synthetic seven-amino-acid analog of ACTH(4-10), N-acetylated for stability. The Institute of Molecular Genetics in Moscow developed it in the 1980s. It was registered as a stroke and TBI adjunct in Russia in 1995. The published Russian evidence base spans stroke recovery, ADHD in children, optic-nerve atrophy, and broader nootropic indications.

The mechanism is well-characterized in the Russian literature. BDNF and NGF upregulation in rat hippocampus. Dopaminergic and serotonergic modulation. Stress-resilience effects in standard preclinical models. The clinical trial base is methodologically older than current Western standards, but it's substantial. Multiple published trials in stroke recovery (typically as an adjunct to standard care) and ADHD show cognitive-endpoint improvements.

The Western literature is comparatively thin. Semax hasn't run a registered ICH-GCP Phase III trial outside Russia.

• Research route in published Russian work: intranasal. Doses 0.1-1.0 mg/day across indications.
• Regulatory: Approved in Russia and several CIS countries for stroke, TBI, and ADHD adjunct use. Not approved by FDA or EMA.
• WADA: Not explicitly listed. Nootropic peptides are subject to interpretation.

Strengths. Deepest cognitive-peptide trial literature in this list. Multiple indication-specific Russian studies. Intranasal route bypasses first-pass metabolism. Well-characterized BDNF mechanism.

Limitations. Trial methodology predates current Western standards. No FDA approval. Zero registered ICH-GCP Phase III trials in Western jurisdictions. The cognitive-enhancement extrapolation in healthy adults isn't directly trial-validated.

Semax

Russian Nootropic

ACTH(4-10) analog 7 aa N-acetylated

The same compound cited across the Russian stroke-recovery and ADHD trial literature. Lab-verified identity and purity.

Shop Semax

2. Selank: anxiolytic with secondary cognitive effects

Selank is a synthetic seven-residue analog of tuftsin (an endogenous immunomodulator), N-acetylated for stability. Like Semax, it came out of the Institute of Molecular Genetics in Moscow. Russian clinicians use it for generalized anxiety disorder and asthenic-neurotic conditions.

The cognitive case for Selank rests on a specific observation. Anxiety reduction without sedation tends to improve attention and working-memory performance. That's different from a direct nootropic mechanism. You're getting cognitive gains as a downstream effect of feeling calmer.

The Russian preclinical literature documents anxiolytic effects without the sedation, withdrawal, or motor impairment seen with benzodiazepines. Mechanistic work has implicated GABA-system enhancement, serotonin stabilization, and IL-6 modulation. Russian clinical trials in generalized anxiety disorder report symptom reduction comparable to medazepam, without the withdrawal profile. Like Semax, the Western trial literature is thin.

• Research route in published Russian work: intranasal. Doses 75-150 mcg/day in published trials.
• Regulatory: Approved in Russia for anxiety. Not approved by FDA or EMA.
• WADA: Not explicitly listed.

Strengths. Anxiolytic without sedation or withdrawal. Consistent Russian preclinical and clinical signal in anxiety populations. Cognitive benefits inferred from anxiety reduction are mechanistically plausible.

Limitations. The direct nootropic effect in healthy adults isn't what the Russian trials studied. Western trial replication is missing.

3. Cerebrolysin: 50+ countries of use, but the 2023 Cochrane is cautious

Cerebrolysin is a porcine brain-derived peptide mixture marketed by EVER Pharma. Clinicians in Russia, China, Mexico, India, and across Eastern Europe use it as an adjunct in stroke, traumatic brain injury, dementia, and Alzheimer's disease. It's not a single peptide. It's a complex mixture of low-molecular-weight peptides and free amino acids derived from purified pig brain protein.

The clinical literature is substantial in volume but mixed on quality. A 2023 Cochrane systematic review and several Western meta-analyses concluded the evidence doesn't support the magnitude of cognitive benefit consumer marketing claims. The 2023 Cochrane review on Alzheimer's and vascular dementia found low-to-moderate quality evidence with effect sizes that didn't reliably translate into clinically meaningful improvement. The acute-stroke literature is inconsistent. Some positive trials, several negative or null trials, and meaningful publication-bias concerns.

Here's the honest read. Cerebrolysin is a real pharmaceutical with decades of international clinical use. The most rigorous current systematic-review synthesis doesn't match the enthusiastic narrative reviews that often inform consumer marketing.

• Clinical use: IV infusion in stroke and TBI settings. IM injection courses for chronic indications.
• Regulatory: Approved in 50+ countries. Not approved by FDA or EMA centrally.
• Notable limitation: Porcine origin means batch-to-batch variability is a documented manufacturing concern.

Strengths. Decades of clinical use. Several positive individual trials. Mechanistic case for neurotrophic adjunct in injury recovery is plausible.

Limitations. The 2023 Cochrane reading is negative on the most stringent interpretation. Effect-size variability across trials is large. It's not a defined single molecule, it's a complex mixture. Not in the peptriva catalog. We've covered it here for class context only.

4. NAD+: mitochondrial-energy support, mixed cognitive data

NAD+ (nicotinamide adenine dinucleotide, oxidized form) isn't a peptide. It's the central electron-transfer cofactor in every cell. We've included it because clinics co-market it with cognitive peptides and the underlying biology (NAD+ decline with age, mitochondrial dysfunction in cognitive decline) is a real mechanistic story.

The Western literature on NAD+ precursors (NMN and NR) for cognitive endpoints is mixed. A handful of small trials in healthy aging populations have shown modest improvements in some cognitive metrics. Others have shown no effect. Direct IV NAD+ studies are smaller, less controlled, and haven't produced a replicable cognitive signal.

The mechanistic case is real. Sirtuin activation, mitochondrial-biogenesis support, DNA-repair pathway upregulation. All well-characterized in cell-culture work. The translation to cognitive outcomes in humans is incomplete.

• Research routes: oral NAD+ precursors (NMN, NR) for systemic effect. IV NAD+ for acute “loading.” Subcutaneous NAD+ research in some protocols.
• Regulatory: Precursors NMN and NR sold as supplements in many jurisdictions. IV NAD+ not FDA-approved as a therapeutic.
• Safety: Generally well-tolerated. High-dose IV use can produce cardiovascular reactions (chest tightness, flushing) during infusion.

Strengths. Well-characterized cofactor biology. The mitochondrial-decline hypothesis of cognitive aging has independent mechanistic support.

Limitations. Mixed Western trial data on cognitive endpoints. Not a peptide. The cognitive translation from cell-culture mechanism is incomplete.

5. SS-31: mitochondrial-targeting peptide with cognitive-relevant biology

SS-31 (Elamipretide) is a four-residue mitochondria-targeting peptide. It selectively partitions into the inner mitochondrial membrane and stabilizes cardiolipin (a key membrane lipid). It's the most mechanistically distinct peptide on this list. Not a neurotransmitter modulator, not a GH-axis tool, but a direct mitochondrial reagent. Its Phase III development has focused on Barth syndrome and primary mitochondrial myopathies. The FDA approved it as Forzinity in 2025 for Barth syndrome.

The cognitive argument for SS-31 rests on the same mitochondrial-dysfunction hypothesis as NAD+. If mitochondrial deficits contribute to cognitive decline, then mitochondrial-targeted intervention should help. The published cognitive-endpoint work in humans is limited. SS-31's clinical development hasn't run a Phase III cognitive-decline trial. The mechanism is novel and the safety profile from the Barth syndrome program is favorable.

• Research route: subcutaneous. Daily dosing in published trials.
• Regulatory: FDA-approved 2025 as Forzinity for Barth syndrome. Not approved for any cognitive indication.
• Safety: Well-tolerated in the Barth syndrome Phase III program.

Strengths. Most mechanistically distinct peptide on this list. FDA approval in a different indication establishes the safety profile. Cardiolipin-stabilization mechanism is well-characterized.

Limitations. No Phase III cognitive trial. The cognitive translation is mechanistic-only.

Adjacent and support peptides

Two compounds frequently appear adjacent to the cognitive list without independent cognitive trial data. DSIP (Delta Sleep-Inducing Peptide) supports cognitive function indirectly through sleep quality. The cognitive endpoint is downstream. Epithalon sits in the Russian Khavinson-school longevity literature with peripheral cognitive claims. The published cognitive-endpoint data is thin and methodologically older.

Optimal stacking protocols

The most-documented cognitive stack in Russian literature is Semax + Selank co-administration. One peptide for cognition and attention, the other for anxiolytic support. The mechanistic rationale is complementary: BDNF and NGF for Semax, GABA and serotonin modulation for Selank. Russian clinicians have used the combination as an adjunct in mixed cognitive-affective complaints.

A second pattern combines a nootropic peptide (Semax or Selank) with a mitochondrial reagent (NAD+ precursor or SS-31). The logic: BDNF-driven plasticity needs ATP to execute, so mitochondrial support sits upstream of the energy budget plasticity requires. The combination is mechanistically coherent but not trial-validated.

A third pattern uses DSIP for sleep quality alongside any of the above. Sleep is one of the largest-effect cognitive interventions known. Restoring slow-wave sleep architecture is a plausible upstream intervention.

Lifestyle considerations

The largest-effect interventions for cognitive function aren't peptide-based. Sleep quality and duration has the largest single-variable effect on cognitive performance across age groups. Aerobic exercise has trial-grade evidence for cognitive function in older adults. Cardiovascular risk-factor management (blood pressure, lipids, glycemic control) is the most-validated intervention for preventing cognitive decline.

Hearing and vision correction are independently linked to cognitive trajectories. Social engagement and continued cognitive challenge (work, learning, social complexity) modulate that trajectory. Honest framing: nootropic peptide stacking sits on top of these foundations, not as a substitute for them.

Selank

Anxiolytic Nootropic

11 mg ≥99% pure Lyophilized

Tuftsin analog, 7 aa, N-acetylated. The same reference compound used across the Russian anxiety-and-cognition trial literature. COA available with each lot.

Learn more

Safety, monitoring, and legal status

Three things to know. First, none of these peptides is FDA-approved for cognitive enhancement in healthy adults. Cerebrolysin is approved in 50+ countries for cognitive decline, but not in the US. SS-31 is FDA-approved for Barth syndrome only.

Second, the WADA picture is permissive for most of this list. Nootropic peptides aren't explicitly listed, though they may be subject to interpretation under the “non-approved substances” clause.

Third, the safety profile across the Russian-school peptides (Semax, Selank) is generally favorable in published trials. Injection-site reactions or mild local irritation are the most common adverse events. Cerebrolysin's IV-use profile includes occasional dizziness and rare hypersensitivity.

If a clinician has raised cognitive-peptide options, these are the questions worth bringing to that conversation:

• What is the specific cognitive complaint, and what does the conventional workup show? Sleep apnea, thyroid dysfunction, B12 deficiency, depression, and hearing loss all produce cognitive symptoms and have specific evidence-based treatments.
• Have we evaluated cardiovascular risk factors? The largest validated cognitive-decline intervention is vascular risk management.
• What outcome metric will we track? Cognitive endpoints are notoriously placebo-sensitive. An objective measure (BDI, MoCA, validated neuropsych battery) is essential.
• What does the trial literature say specifically for my indication? Semax for post-stroke recovery, Selank for anxiety-with-cognitive-symptoms, NAD+ for mitochondrial-decline contexts all have different evidence bases.
• What's the source and chain of custody? Quality control on grey-market neuropeptides is a documented issue.

Frequently asked questions

Is Semax better than Selank for cognitive enhancement? Semax has more direct cognitive-endpoint data. Selank is primarily an anxiolytic with cognitive effects inferred from anxiety reduction. They're mechanistically complementary and often used together in Russian practice.

What about modafinil or racetams? Those aren't peptides and they're out of scope here. Modafinil has FDA approval (narcolepsy, shift-work sleep disorder) and a different evidence profile.

Is Cerebrolysin safe? The international clinical-use safety record is generally favorable. The efficacy reading is the question the Cochrane review challenges, not safety.

How is intranasal Semax dosed? Russian protocols typically use 200-1000 mcg/day intranasally, divided AM/PM. No validated Western protocol exists.